ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 312 filers reported holding ROYALTY PHARMA PLC in Q3 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $129,255 | -16.0% | 4,762 | -5.1% | 0.00% | – |
| Q2 2023 | $153,897 | -16.0% | 5,019 | -1.3% | 0.00% | – |
| Q1 2023 | $183,285 | +10.8% | 5,083 | +21.6% | 0.00% | – |
| Q4 2022 | $165,435 | -5.5% | 4,179 | -3.8% | 0.00% | – |
| Q3 2022 | $175,000 | -10.3% | 4,344 | -6.4% | 0.00% | – |
| Q2 2022 | $195,000 | +29.1% | 4,642 | +8.8% | 0.00% | – |
| Q1 2022 | $151,000 | -2.6% | 4,265 | +9.4% | 0.00% | – |
| Q4 2021 | $155,000 | +34.8% | 3,899 | +22.5% | 0.00% | – |
| Q3 2021 | $115,000 | -59.1% | 3,183 | -53.6% | 0.00% | -100.0% |
| Q2 2021 | $281,000 | -56.6% | 6,861 | -53.8% | 0.00% | -50.0% |
| Q1 2021 | $648,000 | -22.6% | 14,866 | -11.1% | 0.00% | 0.0% |
| Q4 2020 | $837,000 | +11.0% | 16,721 | -6.8% | 0.00% | 0.0% |
| Q3 2020 | $754,000 | +216.8% | 17,942 | +267.2% | 0.00% | +100.0% |
| Q2 2020 | $238,000 | – | 4,886 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $294,957,000 | 88.74% |
| Vantage Consulting Group Inc | 8,705,551 | $379,735,000 | 76.23% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $116,930,000 | 72.07% |
| HARVARD MANAGEMENT CO INC | 10,714,284 | $467,357,000 | 26.11% |
| ROBERT WOOD JOHNSON FOUNDATION | 970,151 | $4,231,798,000 | 21.59% |
| Brown University | 381,759 | $16,652,000 | 11.44% |
| Overbrook Management Corp | 771,155 | $33,638,000 | 7.48% |
| SpiderRock Advisors, LLC | 778,800 | $34,236,000 | 4.79% |
| Renaissance Capital LLC | 452,948 | $19,758,000 | 2.93% |
| Lagoda Investment Management, L.P. | 104,835 | $4,573,000 | 2.28% |